Bone lesions and macrophage inflammatory protein-1 alpha (MIP-1α) in human multiple myeloma

References

• Mundy GR, Raisz LG, Cooper RA et al. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 1974;291:1041–1046.
   PubMed Web of Science ®Google Scholar
• Josse RG, Murray TM, Mundy GR et al. Observations on the mechanism of bone resorption induced by multiple myeloma marrow culture fluids and partially purified osteoclast-activat-ing factor. J Chin Invest 1981;67:1472–1481.
   PubMed Web of Science ®Google Scholar
• Dune BG, Salmon SE, Mundy GR. Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma. Br J Haematol 1981;47:21–30.
   Google Scholar
• Bataille R, Chappard D, Marcelli C et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Chin Invest 1991; 88:62–66.
   PubMed Web of Science ®Google Scholar
• Cozzolino F, Torcia M, Aldinucci D et al. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989; 74:380–387.
   PubMed Web of Science ®Google Scholar
• Bataille R, Klein B, Jourdan M et al. Spontaneous secretion of tumor necrosis factor-beta by human myeloma cell lines. Cancer 1989;63:877–880.
   PubMed Web of Science ®Google Scholar
• Torcia M, Lucibello M, Vannier E et al. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. Exp Hematol 1996;24:868–874.
   PubMed Web of Science ®Google Scholar
• Abildgaard N, Glerup H, Rungby Jet al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 2000;64: 121–129.
   Google Scholar
• Firkin F, Schneider H, Grill V. Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy. L,euk Lymphoma 1998;29:499–506.
   Google Scholar
• Bataille R, Chappard D, Klein B. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimu-lating factor in the pathogenesis of bone lesions in multiple myeloma. Int J Chin Lab Res 1992;21: 283–287.
   Google Scholar
• Choi SJ, Cruz JC, Craig F et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671–675.
   PubMed Web of Science ®Google Scholar
• Han JH, Choi SJ, Kurihara N et al. Macrophage inflammatory protein-lalpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001;97:3349–3353.
   PubMed Web of Science ®Google Scholar
• Abe M, Hiura K, Wilde J et al. Role for macrophage inflammatory protein (MIP)- 1 alpha and MIP-lbeta in the development of osteolytic lesions in multiple myeloma. Blood 2002;100:2195–2202.
   PubMed Web of Science ®Google Scholar
• Barille-Nion S, Bataille R New insights in myeloma-induced osteolysis. Leuk Lymphoma 2003;44:1463–1467.
   PubMed Web of Science ®Google Scholar
• Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 2003;123:758–769.
   Google Scholar
• Hashimoto T, Abe M, Oshima T et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1 alpha and MIP-lbeta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 2004;125: 38–41.
   PubMed Web of Science ®Google Scholar
• Roodman GD, Choi SJ. MIP-1 alpha and myeloma bone disease. Cancer Treat Res 2004;118:83–100.
   PubMedGoogle Scholar
• Rollins BJ. Chemokines. Blood 1997;90:909–928.
   PubMed Web of Science ®Google Scholar
• Wolpe SD, Davatelis G, Sherry B et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med 1988;167: 570–581.
   PubMed Web of Science ®Google Scholar
• Dung J, de Wynter EA, Kasper C et al. Expression of macrophage inflammatory protein-1 receptors in human CD34( +) hematopoietic cells and their modulation by tumor necrosis factor-alpha and interferon-gamma. Blood 1998;92: 3073–3081.
   PubMed Web of Science ®Google Scholar
• del Pozo MA, Sanchez-Mateos P, Nieto M et al. Chemokines regulate cellular polarization and adhesion receptor redistribu-tion during lymphocyte interaction with endothelium and extracellular matrix. Involvement of cAMP signaling pathway. J Cell Biol 1995;131:495–508.
   Google Scholar
• Kukita T, Nomiyama H, Ohmoto Y et al. Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment. Lab Invest 1997;76:399–406.
   PubMed Web of Science ®Google Scholar
• Scheven BA, Milne JS, Hunter I et al. Macrophage-inflammatory protein-lalpha regulates preosteoclast differen-tiation in vitro. Biochem Biophys Res Commun 1999; 254:773–778.
   PubMed Web of Science ®Google Scholar
• Combadiere C, Ahuja SK, Tiffany HL et al. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J Leukoc Biol 1996;60:147–152.
   PubMed Web of Science ®Google Scholar
• Calvani N, Silvestris F, Cafforio P et al. Osteoclast-like cell formation by circulating myeloma B lymphocytes: role of RANK-L. L,euk Lymphoma 2004;45:377–380.
   PubMed Web of Science ®Google Scholar
• Nakagawa N, Kinosaki M, Yamaguchi K et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998; 253:395–400.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Colla S, Morandi F et al. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment. Haematologica 2004;89:1118–1123.
   PubMed Web of Science ®Google Scholar
• Lentzsch S, Gries M, Janz M et al. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003;101:3568–3573.
   PubMed Web of Science ®Google Scholar
• Dung J, Schmucker U, Duhrsen U. Differential expression of chemokine receptors in B cell malignancies. Leukemia 2001; 15:752–756.
   Google Scholar
• Michigami T, Shimizu N, Williams PJ etal. Cell—cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteo-clast-stimulating activity. Blood 2000;96:1953–1960.
   Google Scholar
• Okamatsu Y, Kim D, Battaglino R et al. MIP-1 gamma promotes receptor-activator-of-NF-kappa-B-ligand-induced osteoclast formation and survival. J Immunol 2004;173: 2084–2090.
   PubMed Web of Science ®Google Scholar
• Uneda S, Hata H, Matsuno F et al. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 2003;120:53–55.
   PubMed Web of Science ®Google Scholar
• Magrangeas F, Nasser V, Avet-Loiseau H et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 2003;101:4998— 5006.
   PubMed Web of Science ®Google Scholar
• Choi SJ, Oba T, Callander NS et al. AML-1A and AML-1B regulation of MIP-lalpha expression in multiple myeloma. Blood 2003;101:3778–3783.
   PubMed Web of Science ®Google Scholar
• Terpos E, Politou M, Szydlo R et al. Serum levels of macrophage inflammatory protein-1 alpha (MIP-lalpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003;123: 106–109.
   PubMed Web of Science ®Google Scholar
• Choi SJ, Oba Y, Gazitt Y et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone de-struction in a model of myeloma bone disease. J Chin Invest 2001108:1833-1841.
   PubMed Web of Science ®Google Scholar
• Sezer O, Heider U, Zavrski I et al. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003; 101:2094–2098.
   PubMed Web of Science ®Google Scholar